TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01042873

Intervention type: DRUG
Group type: OTHER
Intervention: 3 hours intravenous dobutamine
Description: Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
Study: NCT00206596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Once daily via subcutaneous injection for up 22 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily via subcutaneous injection for up 22 weeks
Study: NCT02024594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide-Oxygen conscious sedation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Study: NCT04502849

Intervention type: PROCEDURE
Intervention: Bypass surgery
Description: Creating a bypass with graft or vein.

Intervention type: PROCEDURE
Intervention: Endovascular angioplasty/stenting
Description: Performing an angioplasty with or without stenting in stenosis.

Intervention type: PROCEDURE
Intervention: Hybrid surgery
Description: Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.

Intervention type: DRUG
Intervention: Vitamin E
Description: 100 mg Vitamin E per os 1 per day (1 month).

Intervention type: DRUG
Intervention: Vitamin E
Description: 100 mg Vitamin E per os 1 per day (1 month).

Intervention type: DRUG
Intervention: Vitamin E
Description: 100 mg Vitamin E per os 1 per day (1 month).

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower limbs arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower limbs arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower limbs arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower limbs arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower limbs arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for apoptosis and endothelial dysfunction markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for apoptosis and endothelial dysfunction markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for apoptosis and endothelial dysfunction markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for apoptosis and endothelial dysfunction markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for apoptosis and endothelial dysfunction markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial wall sampling
Description: Arterial wall sampling for apoptosis markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial wall sampling
Description: Arterial wall sampling for apoptosis markers.
Study: NCT01858350

Intervention type: OTHER
Group type: OTHER
Intervention: Active Music Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Passive Music Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Distraction Therapy
Study: NCT01857973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop
Description: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
Study: NCT00623636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0004
Description: MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
Study: NCT02342041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUVN-G3031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUVN-G3031
Study: NCT01913340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 1000 U/kg/dose IV x 5 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo: NS IV x 5 doses
Study: NCT02342041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00973089

Intervention type: OTHER
Group type: OTHER
Intervention: Incomplete caries removal in primary teeth
Description: Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
Study: NCT04053673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBN-2397
Description: an oral PARP7 Inhibitor
Study: NCT03702634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spiritual Care Assessment and Intervention (SCAI) framework
Description: The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
Study: NCT02452528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5 or 1.0 mg/day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: 0.5 or 1.0 mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: 300 mg/day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: 300 mg/day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: 50 mg orally as pretreatment antihistamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diphenhydramine
Description: 50 mg orally as pretreatment antihistamine
Study: NCT00401245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Titration 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Titration 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Titration 25 mg, 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Titration 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tapering placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Tapering 50 mg, placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Tapering 50 mg, 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desvenlafaxine succinate sustained release
Description: Tapering 50 mg QOD
Study: NCT01606241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha Peptide Vaccine
Description: Given ID
Study: NCT03906084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticotomy and low laser therapy
Description: Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy facilitated Orthodontics
Description: Corticotomy is carried out under local anesthesia in right side.
Study: NCT03490565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
Study: NCT03507725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Prostate needle biopsy under local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Biopsy
Description: Prostate needle biopsy under local anesthesia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
Study: NCT00391716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 900mg
Description: 900 mg gabapentin daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling
Description: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling
Description: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral counseling
Description: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose capsule compounded to mimic gabapentin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1800mg
Description: 1800 mg gabapentin daily for 12 weeks
Study: NCT03777605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.4 MG
Description: The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project
Study: NCT02918942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanoseal
Description: All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
Study: NCT04470037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-P
Description: DAAOI-P 250-1500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch pill
Study: NCT01226316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
Study: NCT00835367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-benazepril 10 mg-20 mg capsules
Description: 1 x 10-20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® 10 mg-20 mg capsule
Description: 1 x 10-20 mg
Study: NCT02322840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twelve TMVR Implant
Description: Implantation of the Twelve TMVR System -Apical

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System
Description: Implant of Intrepid valve -Transfemoral
Study: NCT03592264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-3424
Description: liquid formulation for Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-3424
Description: liquid formulation for Intravenous infusion
Study: NCT04591080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUMMETAL Orthodontic Wire
Description: Orthodontic archwire made of TiNbTaZr alloy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless Steel (CrNi)
Description: Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022
Study: NCT01822379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melanocyte Keratinocyte transplantation
Description: Transplantation of cells prepared with dispase
Study: NCT02337556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptamen Bariatric
Description: Commercially available enteral diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replete
Description: Commercially available enteral diet
Study: NCT02007460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: multidirectional unilateral hopping exercise
Study: NCT04210960

Intervention type: RADIATION
Intervention: Magentic resonanace imaging
Description: The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.

Intervention type: RADIATION
Intervention: Magentic resonanace imaging
Description: The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.

Intervention type: RADIATION
Intervention: Magentic resonanace spectroscopy
Description: Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.

Intervention type: RADIATION
Intervention: Magentic resonanace spectroscopy
Description: Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
Study: NCT01649869

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
Study: NCT00793806

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
Study: NCT01762371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Khalifa Therapy
Description: One hour of Khalifa's therapy which is specially applied pressure to the skin.
Study: NCT04388488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONNECT TF adaptable socket system
Description: Prefabricated, adaptable socket system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Any conventional handmade socket
Description: Subjects current socket
Study: NCT04436120

Intervention type: PROCEDURE
Group type: OTHER
Intervention: De novo tumor tissue biopsy
Description: De novo tissue biopsy performed following disease progression

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Research blood draws
Description: Blood biospecimens collected following disease progression
Study: NCT03053141

Intervention type: DEVICE
Intervention: Rhythmia Mapping System
Description: The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
Study: NCT04111354

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: Pacemaker implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: Pacemaker implantation
Study: NCT03508674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Magnetic Surgical System
Description: use of surgical tool
Study: NCT05615883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEP Group Walking Sessions
Description: The AEP Program consists in a single walking session on a treadmill lasting 80 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEP Group Walking Sessions
Description: The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
Study: NCT03753516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic - Vaginal Cuff Closure
Description: All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal- Vaginal Cuff Closure
Description: All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
Study: NCT00931541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6088
Description: Oral solution. Each subject will receive a single-dose of AZD6088.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution. Each subject will receive a single-dose of placebo.
Study: NCT01394185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 120mg/day
Description: Participants receive 40mg dronabinol 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 240mg/day
Description: Participants receive 80mg dronabinol 3 times daily
Study: NCT03433287

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF-PET/MRI
Description: PET/MRI scan after injection of 18F-labelled sodium fluoride
Study: NCT03238092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: testosterone gel daily during the late luteal phase.
Study: NCT03428347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEMab
Description: drug for emergency prevention of Ebola based on recombinant monoclonal antibodies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEMab
Description: drug for emergency prevention of Ebola based on recombinant monoclonal antibodies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamEMab
Description: drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
Study: NCT00271245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200 µg selenium as selenate
Description: 200 µg selenium as selenate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 µg selenium as selenate
Description: 400 µg selenium as selenate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200 µg selenium as selenomethionine
Description: 200 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo